Portal Vein Thrombosis in a Patient With COVID-19

Ofosu, Andrew; Ramai, Daryl; Novikov, Anastasia; Venugopal, Sushma

doi:10.14309/ajg.0000000000000781

Cited by 22 publications

(18 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 641 articles were screened, 21 of which were selected according to the above mentioned criteria 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 . The included articles were all case reports (except for one case series [10] ), and contained description of 21 cases.…”

Section: Resultsmentioning

confidence: 99%

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

Buso¹,

Becchetti²,

Berzigotti³

2021

Digestive and Liver Disease

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Resultsmentioning

confidence: 99%

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

Buso¹,

Becchetti²,

Berzigotti³

2021

Digestive and Liver Disease

View full text Add to dashboard Cite

show abstract

“…They are most commonly caused by myeloproliferative disorders, antiphospholipid syndrome, or other hypercoagulable disorders [ 8 ]. Three cases of portal vein thrombosis in COVID-19 patients have been reported [ 3 , 9 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

Clostridium Difficile and COVID-19: Novel Risk Factors for Acute Portal Vein Thrombosis

Rokkam

Sridharan

Vegunta

et al. 2021

Case Reports in Vascular Medicine

View full text Add to dashboard Cite

The COVID-19 pandemic has created an unprecedented global health care crisis. COVID-19 patients are found to have increased thrombotic risk. Despite being on prophylactic anticoagulation, many develop serious arterial and venous thromboembolic events. Emerging reports indicate COVID-19 may be considered a novel risk factor for portal vein thrombosis. Although, intra-abdominal infections are identified as risk factors, clostridium difficile colitis has not been typically seen as a risk factor for PVT. We report a case of an elderly female with a recent diagnosis of COVID-19 and no prior history of cirrhosis or malignancy who presented with diarrhea due to clostridium difficile infection. She developed sudden onset severe abdominal pain during the course of hospitalization. Acute portal vein thrombosis was identified on CT imaging of the abdomen, and she improved well with therapeutic anticoagulation. Acute portal vein thrombosis usually results from a combination of local and systemic prothrombotic risk factors. The combination of local infection by clostridium difficile and COVID-19 coagulopathy led to development of portal vein thrombosis in our patient. To the best of our knowledge, this is the first case of portal vein thrombosis reported in a patient with clostridium difficile infection in the setting of COVID-19 coagulopathy. During the current pandemic, clinicians should strongly consider abdominal imaging in patients presenting with abdominal pain due to clostridium difficile infection in the setting of COVID-19 to rule out complications such as portal vein thrombosis. Early diagnosis and treatment of portal vein thrombosis prevent complications of portal hypertension and intestinal infarctions.

show abstract

“…Franco-Moreno et al [6] Ofosu et al [7] La Mura et al [8] Del Hoyo et al [9] de Barry et al [10] Ignat et al [ Wbc white blood cells, Hb hemoglobin, ALP alkaline phosphatase, AST aspartate transaminase, ALT alanine transaminase, CRP c-reactive protein, PT prothrombin tine, INR international normalized ratio, PTT partial thromboplastin time, M male, F female, wnl within normal limits, CT computed tomography, PNH paroxysmal nocturnal hemoglobinuria, CMV cytomegalovirus, EBV Epstein-Barr virus, HSV herpes simplex virus, ANA anti-nuclear antibody, ANCA anti neutrophil cytoplasmic antibody, AMA anti mitochondrial antibody, ASMA anti smooth muscle antibody, anti-LKM-1 antiliver kidney microsomal antibody, NR not reported, SIH still in hospital at the writing of respective manuscript, AC anti-coagulation, Reference values-Wbc 4-10 10 9 /L)/, Hb 12-15 g/dL, platelets 150-400 × 10 3 μL, ALP 40-109 U/L, AST 5-40 U/L, ALT 9-59 U/L, Total. Bilirubin 0.1-1.1 mg/dL, d -dimer < 500 μg/L, CRP < 0.5 mg/dL.…”

Section: Authormentioning

confidence: 99%

Splanchnic vein thrombosis in COVID-19: A review of literature

Singh

Kaur

Maroules

2020

Digestive and Liver Disease

View full text Add to dashboard Cite

Splanchnic vein thrombosis in COVID-19: A review of literature Dear Editor , Coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) can predispose to both venous and arterial thromboembolism [1-4]. Splanchnic vein thrombosis (SVT) including portal, mesenteric, splenic vein thrombosis and the Budd-Chiari syndrome, is a manifestation of unusual site venous thromboembolism. SVT usually occurs in association with cirrhosis, liver malignancy or in patients with inherited or acquired thrombophilia [5]. Limited literature is available regarding SVT in COVID-19. We did an extensive literature review on COVID-19 associated SVT. We searched PubMed for this literature review using search terms 'COVID-19 and splanchnic vein thrombosis, 'COVID-19 and portal vein thrombosis', 'COVID-19 and mesenteric vein thrombosis', COVID-19 and Budd-Chiari syndrome', COVID-19 and hepatic vein thrombosis' and 'COVID-19 and splenic vein thrombosis'. All the case reports with COVID-19 associated SVT so far were reviewed, and relevant data was abstracted from these studies. COVID-19 diagnosis was made by PCR assay except in one patient it was negative (suspected COVID-19). The clinical features, laboratory values and outcome are summarized in Table 1 [6-11]. We found total of six patients. The median age of patients was 58 years (range 27-79 years) and 50% were male. Presenting symptoms were vomiting, abdominal pain, diarrhea, fever, shortness of breath, jaundice and altered mental status. None of the patients had cirrhosis or hepatocellular cancer. Work up done to rule out known associated inherited or acquired

show abstract

Portal Vein Thrombosis in a Patient With COVID-19

Cited by 22 publications

References 5 publications

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

Clostridium Difficile and COVID-19: Novel Risk Factors for Acute Portal Vein Thrombosis

Splanchnic vein thrombosis in COVID-19: A review of literature

Contact Info

Product

Resources

About